Curanex engages Strategic Investor Relations to enhance Curanex’s visibility

Curanex (CURX) Pharmaceuticals has engaged Strategic Investor Relations, a premier investor relations firm, to enhance Curanex’s visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company’s innovative pipeline and strategic initiatives. With this new partnership, Curanex aims to refine its communication strategies and investor relations activities to ensure stakeholders are fully informed and engaged with the Company’s progress and prospects. Strategic Investor Relations will assist Curanex in highlighting its botanical drug development approach, which encompasses high-efficacy botanical drugs with de-risked clinical pathways and its positioning in the rapidly expanding botanical drug market.